Announcement

Collapse
No announcement yet.

Pfizer unveils its oral SARS-CoV-2 inhibitor

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Pfizer unveils its oral SARS-CoV-2 inhibitor

    The antiviral candidate is the first orally administered compound to enter clinical trials that targets the virus’s main protease

    by Bethany Halford

    APRIL 7, 2021 | APPEARED IN VOLUME 99, ISSUE 13

    Drugmaker Pfizer revealed its oral COVID-19 antiviral clinical candidate PF-07321332 on Tuesday at the American Chemical Society Spring 2021 meeting. The compound, which is currently in Phase 1 clinical trials, is the first orally administered compound in the clinic that targets the main protease (also called the 3CL protease) of SARS-CoV-2, the virus that causes COVID-19. By inhibiting the main protease, PF-07321332 prevents the virus from cleaving long protein chains into the parts it needs to reproduce itself. Dafydd Owen, director of medicinal chemistry at Pfizer, presented the compound in a symposium of the Division of Medicinal Chemistry.

    ... Because PF-07321332 can be taken orally, as a pill or capsule, it could be given outside of hospitals if it proves to be safe and effective. People who have been exposed to SARS-CoV-2 could take it as a preventative measure, for example.

    https://cen.acs.org/acs-news/acs-mee...m_campaign=CEN

  • #2
    bump this

    Comment

    Working...
    X